ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Alabama » Pulmonary Disease

Top Pulmonary Disease Prescribers in Alabama

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
KUMUDCHANDRA SHAH MD

Pulmonary Disease

12,420

$652K

589
421 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

12%
patients receiving schedule three controlled substances

Avg: 4%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 52%

$53
Average prescription price

Avg: $135

RUSSELL BEATY MD

Pulmonary Disease

9,774

$727K

621
476 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

11%
patients receiving schedule three controlled substances

Avg: 4%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

36%
prescriptions for brand name drugs

Avg: 52%

$74
Average prescription price

Avg: $135

JAN WESTERMAN M.D.

Pulmonary Disease

8,896

$1.08M

653
283 are 65+

32%
patients receiving schedule two controlled substances

Avg: 1%

14%
patients receiving schedule three controlled substances

Avg: 4%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

38%
prescriptions for brand name drugs

Avg: 52%

$121
Average prescription price

Avg: $135

MAHER SAHAWNEH M.D.

Pulmonary Disease

8,676

$511K

560
396 are 65+

5%
patients receiving schedule two controlled substances

Avg: 1%

17%
patients receiving schedule three controlled substances

Avg: 4%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 52%

$59
Average prescription price

Avg: $135

OLIVER CRAWFORD MD

Pulmonary Disease

7,387

$463K

266
150 are 65+

6%
patients receiving schedule two controlled substances

Avg: 1%

30%
patients receiving schedule three controlled substances

Avg: 4%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 52%

$63
Average prescription price

Avg: $135

JOHN MCATEE MD

Pulmonary Disease

6,444

$387K

532
442 are 65+

3%
patients receiving schedule two controlled substances

Avg: 1%

20%
patients receiving schedule three controlled substances

Avg: 4%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 52%

$60
Average prescription price

Avg: $135

ALLAN GOLDSTEIN MD

Pulmonary Disease

6,241

$317K

387
301 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

16%
patients receiving schedule three controlled substances

Avg: 4%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 52%

$51
Average prescription price

Avg: $135

EDSEL HOLDEN MD

Pulmonary Disease

6,149

$594K

537
356 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

6%
patients receiving schedule three controlled substances

Avg: 4%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

34%
prescriptions for brand name drugs

Avg: 52%

$97
Average prescription price

Avg: $135

DEVI MISRA M.D.

Pulmonary Disease

5,257

$271K

371
277 are 65+

3%
patients receiving schedule two controlled substances

Avg: 1%

24%
patients receiving schedule three controlled substances

Avg: 4%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 52%

$52
Average prescription price

Avg: $135

WILLIAM GEWIN M.D.

Pulmonary Disease

4,783

$364K

310
259 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

7%
patients receiving schedule three controlled substances

Avg: 4%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 52%

$76
Average prescription price

Avg: $135

MICHAEL CRAIN M.D.

Pulmonary Disease

4,499

$867K

392
295 are 65+

4%
patients receiving schedule two controlled substances

Avg: 1%

8%
patients receiving schedule three controlled substances

Avg: 4%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

40%
prescriptions for brand name drugs

Avg: 52%

$193
Average prescription price

Avg: $135

ROBERT PERCY M.D.

Pulmonary Disease

4,450

$207K

322
203 are 65+

4%
patients receiving schedule two controlled substances

Avg: 1%

22%
patients receiving schedule three controlled substances

Avg: 4%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 52%

$47
Average prescription price

Avg: $135

MARC GOTTLIEB M.D.

Pulmonary Disease

4,108

$284K

257
202 are 65+

5%
patients receiving schedule two controlled substances

Avg: 1%

14%
patients receiving schedule three controlled substances

Avg: 4%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

36%
prescriptions for brand name drugs

Avg: 52%

$69
Average prescription price

Avg: $135

LUTHER CORLEY M.D.

Pulmonary Disease

3,950

$823K

397
303 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

3%
patients receiving schedule three controlled substances

Avg: 4%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

62%
prescriptions for brand name drugs

Avg: 52%

$208
Average prescription price

Avg: $135

GERALD DEY M.D.

Pulmonary Disease

3,897

$461K

536
385 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

2%
patients receiving schedule three controlled substances

Avg: 4%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

59%
prescriptions for brand name drugs

Avg: 52%

$118
Average prescription price

Avg: $135

GORDON WARNER MD

Pulmonary Disease

3,785

$1.56M

472
336 are 65+

14%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 4%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

59%
prescriptions for brand name drugs

Avg: 52%

$412
Average prescription price

Avg: $135

BRUCE KEY M.D.

Pulmonary Disease

3,666

$375K

374
302 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

3%
patients receiving schedule three controlled substances

Avg: 4%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

45%
prescriptions for brand name drugs

Avg: 52%

$102
Average prescription price

Avg: $135

MARIA JOHNSON M.D.

Pulmonary Disease

3,153

$376K

390
287 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

3%
patients receiving schedule three controlled substances

Avg: 4%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

57%
prescriptions for brand name drugs

Avg: 52%

$119
Average prescription price

Avg: $135

LAURENCE CARMICHAEL MD

Pulmonary Disease

3,151

$223K

331
260 are 65+

5%
patients receiving schedule two controlled substances

Avg: 1%

6%
patients receiving schedule three controlled substances

Avg: 4%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

31%
prescriptions for brand name drugs

Avg: 52%

$71
Average prescription price

Avg: $135

ALLAN SEIBERT MD

Pulmonary Disease

2,922

$479K

342
271 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

8%
patients receiving schedule three controlled substances

Avg: 4%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

57%
prescriptions for brand name drugs

Avg: 52%

$164
Average prescription price

Avg: $135

ROHIT PATEL M.D.

Pulmonary Disease

2,890

$499K

402
242 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 4%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

67%
prescriptions for brand name drugs

Avg: 52%

$173
Average prescription price

Avg: $135

WILLIAM HAYS M.D.

Pulmonary Disease

2,873

$224K

326
268 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

5%
patients receiving schedule three controlled substances

Avg: 4%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

43%
prescriptions for brand name drugs

Avg: 52%

$78
Average prescription price

Avg: $135

MOHAMMAD AZAM MD

Pulmonary Disease

2,742

$345K

315
196 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 4%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

57%
prescriptions for brand name drugs

Avg: 52%

$126
Average prescription price

Avg: $135

EMILY REHBERG MD

Pulmonary Disease

2,468

$476K

296
190 are 65+

4%
patients receiving schedule two controlled substances

Avg: 1%

6%
patients receiving schedule three controlled substances

Avg: 4%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

66%
prescriptions for brand name drugs

Avg: 52%

$193
Average prescription price

Avg: $135

JASON ROLLINS MD

Pulmonary Disease

2,361

$288K

300
199 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

4%
patients receiving schedule three controlled substances

Avg: 4%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

47%
prescriptions for brand name drugs

Avg: 52%

$122
Average prescription price

Avg: $135

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank